Page 15 - Clinical Trial Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from PR Newswire. The AP news staff was not involved in its creation. Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer March 16, 2021 GMT Not intended for UK-based media DARMSTADT, Germany, March 16, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliar...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase...

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting News provided by Share this article Share this article THOUSAND OAKS, Calif., Feb. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-...

Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III [email protected] Lung 037 study and the extensive [email protected] clinical trial program for the potential first-in-class investigational bifunctional immunotherapy bintrafusp alfa, in difficult-to-treat cancers, including biliary tract cancer (BTC) and cervical cancer. The comprehensive [email protected] program is designed to assess the impact of bintrafusp alfa across distinct cancers and settings where TGF-β is thought to play a driv...

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Amgen and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral … Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE tria...